1stOncology™: Cancer Intelligence Service – Page 62 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

On September 8, 2026 Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, reported participation at the following investor conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2026
Format: Virtual fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ET
Location: New York, NY

A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

(Press release, Tyra Biosciences, SEP 8, 2026, View Source [SID1234670642])

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

On September 8, 2026 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived for a limited time following the presentation.

(Press release, Protara Therapeutics, SEP 8, 2026, View Source [SID1234670640])

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

On September 8, 2026 Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, reported that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET.

The webcast will be posted to Tempest’s website at View Source and will be archived for two weeks following the presentation.

(Press release, Tempest Therapeutics, SEP 8, 2026, View Source/news-releases/news-release-details/tempest-present-hc-wainwright-28th-annual-global-investment [SID1234670639])

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

On September 8, 2026 Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, reported that Travis Whitfill Ph.D., MPH, Azitra’s Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City.

In the prerecorded presentation, Dr. Whitfill will provide an update on Azitra’s recent progress and key pipeline activities, including initial data from the ATR-COSF program supporting the Company’s strategy to leverage its microbial genetic engineering platform beyond traditional therapeutics, including cosmetic applications targeting fine lines and wrinkles. He will also discuss continued enrollment in the first cohort of the Phase 1/2 clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash.

Details of the presentation are as follows:

Event:

H.C. Wainwright 28th Annual Global Investment Conference

Date:

September 14-16, 2026

Presenter:

Travis Whitfill Ph.D., MPH, Co-founder and Chief Operating Officer

Webcast Link:

View Source

During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, highlighting the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

(Press release, Azitra, SEP 8, 2026, View Source [SID1234670638])

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

On September 8, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

H.C. Wainwright 28th Annual Global Investment Conference

Date:

Monday, September 14th

Time:

4:00pm ET

Format:

Fireside Chat & 1×1 Meetings

To register and view the presentation, please CLICK HERE.

An archived webcast of the Fireside Chat will be available on the Events Page in the investor section of TuHURA’s website.

(Press release, TuHURA Biosciences, SEP 8, 2026, https://ir.tuhurabio.com/news-events/press-releases/detail/49/tuhura-biosciences-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference [SID1234670637])